ResearchSS-31 and Mitochondrial Peptides: A 2026 Research Update
SS-31 (elamipretide) is a mitochondria-targeted peptide that became the base molecule behind FORZINITY, the first FDA-approved mitochondrial peptide therapy, in October 2025. This update covers what that approval does and doesn't change for SS-31 research materials sold in the UK.
Read article






